Tuberculosis vaccine 1 is under clinical development by Chengdu Keen Biotechnology and currently in Phase III for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to GlobalData, Phase III drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tuberculosis vaccine 1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tuberculosis vaccine 1 overview
Vaccine is under development for the treatment of non-muscle invasive bladder cancer and tuberculosis.. It is administered through intravesical route.
Chengdu Keen Biotechnology overview
Chengdu Keen Biotechnology (Keen Biotechnology) focuses on the field of biomedicine, mainly engaged in the R&D and industrialization of tuberculosis diagnostic biological products and therapeutic vaccines. Keen Biotechnology is headquartered in Chengdu, Sichuan, China.
For a complete picture of Tuberculosis vaccine 1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.